Држава: Арменија
Језик: Енглески
Извор: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
diclofenac (diclofenac diethylammonium)
Help S.A.
M02AA15
diclofenac (diclofenac diethylammonium)
10mg/g
gel for external use
25g aluminium tube
OTC
Registered
2017-04-25
SUMMARY PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Vurdon 1% Gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1g of Vurdon Gel contains 11.6 mg of the active substance diclofenac diethylammonium, which corresponds to 10 mg diclofenac sodium. For full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Gel White gel with characteristic odour. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the local symptomatic relief of pain and inflammation in: - trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises - localised forms of soft tissue rheumatism It is recommended that the treatment be reviewed after 14 days in these indications. For the treatment of osteoarthritis of superficial joints such as the knee. In the treatment of osteoarthritis, therapy should be reviewed after 4 weeks. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults_: Vurdon gel should be rubbed gently into the skin. Depending on the size of the affected site to be treated 2-4g (a circular shaped mass approximately 2.0-2.5cm in diameter) should be applied 3 - 4 times a daily. After application, the hands should be washed unless they are the site being treated. _Use in the elderly_: The usual adult dosage may be used. _Children and adolescents: _There are insufficient data on efficacy and safety available for the children and adolescents below 12 years of age (see also contraindications section 4.3). In children aged 12 years and over, if this product is required for more than 7 days for pain relief or if the symptoms worsen the patient/parents of the adolescent is/are advised to consult a doctor. If large areas of the body are covered with gel, systemic absorption will be greater and the risk of side-effects increased, especially if the therapy is used frequently. 4.3 CONTRAINDICATIONS • Patients with or without chronic asthma in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid (aspirin) or other non- steroidal anti- inflammatory drug Прочитајте комплетан документ